Melanoma
Daniel G. Coit, Robert H.I. Andtbacka, Christopher Keram Bichakjian et al. · Journal of the National Comprehensive Cancer Network · 2009
In 2008, an estimated 62,480 new cases of melanoma will have been diagnosed and approximately 8420 patients will have died of the disease in the United States. 1 However, these projections for new cases may represent a substantial underestimation, because many superficial and in situ melanomas treated in the outpatient setting are not reported.The incidence of melanoma continues to increase dramatically.Melanoma is increasing in men more rapidly than any other malignancy and more rapidly in women than any other malignancy except lung cancer.For someone born in the United States in 2005, the lifetime risk for developing melanoma may be as high as 1 in 55. 2 Melanoma ranks second to adult leukemia in terms of loss of years of potential life, per death.The median age at diagnosis is 59 years.
Cited by 126 works. doi:10.6004/jnccn.2009.0020
Authors
- Daniel G. Coit
- Robert H.I. Andtbacka
- Christopher Keram Bichakjian
- Raza A. Dilawari
- Dominick J. DiMaio
- Valerie Guild
- Allan C. Halpern
- Frank Stephen Hodi
- Mohammed Kashani–Sabet
- Julie R. Lange
- Anne C. Lind
- Lainie P. Martin
- Mary C. Martini
- Scott Knowles Pruitt
- Merrick I. Ross
- Stephen Francis Sener
- Susan M. Swetter
- Kenneth K. Tanabe
- Vijay Trisal
References
- AJCC Cancer Staging Manual
- Computed Tomography — An Increasing Source of Radiation Exposure
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
- Sentinel-Node Biopsy or Nodal Observation in Melanoma
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
- Efficacy of 2-cm Surgical Margins for Intermediate-Thickness Melanomas (1 to 4 mm) Results of a Multi-institutional Randomized Surgical Trial